The ACTION-1 interim readout delivers the highest-tier evidence signal possible — a Phase 3 RCT primary endpoint met at interim analysis — in a post-Lutathera GEP-NET population where no approved therapy exists. That combination of pivotal-level evidence and genuine unmet need is the strongest regulatory foundation BMS could present to the FDA. The closest mechanistic precedent that clears the fit bar is Lutathera (lutetium-177 DOTATATE, NETTER-1, Phase 3 RCT, PFS primary endpoint, SSTR-positive GEP-NETs): same biological target, same radioligand delivery class, same tumor type, same endpoint structure. [1] NETTER-1 demonstrated that the FDA accepts PFS as a primary endpoint for SSTR-targeted radiopharmaceutical approval without requiring OS significance — a template ACTION-1 replicates in a later, more refractory line. The radionuclide distinction (alpha vs. beta emission) is mechanistically meaningful and provides a coherent biological rationale for activity post-Lutathera, but it also means Lutathera's safety precedent does not transfer directly; actinium-225's alpha-particle profile — renal dosimetry, hematologic burden in a pre-irradiated population — requires independent characterization. [2] Two material evidence gaps dominate the risk picture: overall survival data are not reported at interim, and the comparator arm composition is undisclosed in the press release, preventing independent assessment of the PFS benefit's clinical magnitude. [1][3] On the competitive side, a Phase 2 randomized Lutathera re-treatment trial (EUCT 2021-001306-30, enrollment 176, ongoing) and a Phase 3 lutetium-177 edotreotide program (EUCT 2021-001086-20, enrollment 250, recruitment ended) represent the nearest pipeline threats, though neither has reported pivotal data in the post-Lutathera slot. [4][5] Payers will benchmark RYZ101 against Lutathera's established pricing tier while demanding OS and quality-of-life data before granting unrestricted reimbursement — the sharpest near-term risk is that an accelerated approval conditioned on OS confirmation delays full commercial uptake.
ACTION-1 is a Phase 3 RCT that met its primary PFS endpoint at interim — highest evidence tier — but overall survival data are not reported and the comparator arm is unspecified, preventing independent verification of clinical meaningfulness or magnitude of benefit. [3]
| Indication | Advanced somatostatin receptor–expressing gastroenteropancreatic neuroendocrine tumors (GEP-NETs) |
| Drug | RYZ101 |
| Mechanism of Action | Actinium-225 radiopharmaceutical |
| Company | Bristol Myers Squibb |
| Trial Phase | Phase 3 |
| Trial Acronym | ACTION-1 |
| NCT ID | NCT05477576 |
| Category | Clinical Trial Event |
| Sub Category | Topline Results Positive |
| Therapeutic Area | Oncology |
| Acquisition Value | $4.1 billion |
| Acquired Company | RayzeBio |
| Comparator Drug | Lutathera |
| Radioisotope | Actinium-225 |
| Regulatory Designation | Orphan Drug Status |
| Primary Endpoint | Progression-Free Survival (PFS) |
| PFS Events for Measurement | 143 |
| Global Prevalence of GEP-NETs | Fewer than 200,000 patients |
| Other Indications in Development | Hormone receptor–positive metastatic breast cancer |
BMS's RYZ101 Hits Primary Endpoint in Phase 3 GEP-NET Trial
Bristol Myers Squibb (BMS) announced that its experimental radiopharmaceutical therapy, RYZ101, met its primary endpoint of statistically significant and clinically meaningful improvement in progression-free survival (PFS) in an interim analysis of the Phase 3 ACTION-1 trial. The study enrolled patients with advanced somatostatin receptor–expressing gastroenteropancreatic neuroendocrine tumors (GEP-NETs) that had progressed after treatment with Novartis’ Lutathera. RYZ101, acquired through BMS's $4.1 billion RayzeBio acquisition, is an actinium-225-based therapy. Safety results were consistent with its known profile, and BMS plans to discuss regulatory submission with the FDA.
- RYZ101 demonstrated a statistically significant and clinically meaningful improvement in progression-free survival (PFS) in the Phase 3 ACTION-1 trial. This achievement, measured by blinded independent central review, marks a crucial step for the actinium-225-based radiopharmaceutical in treating advanced GEP-NETs, a rare cancer type where patients often progress after standard lutetium-177-based therapies like Lutathera.
- The success of RYZ101 validates Bristol Myers Squibb's $4.1 billion acquisition of RayzeBio, which closed in early 2024. RYZ101, made with actinium-225, is positioned as a next-generation radiopharma candidate, addressing a significant unmet need in GEP-NETs. The drug previously received orphan drug status from the FDA, further supporting its development and potential regulatory pathway.
- The safety profile of RYZ101 in the ACTION-1 trial was consistent with previous findings, including a Phase 1b study where it was well tolerated with no treatment-related serious adverse events. BMS plans to engage with the FDA to discuss next steps for a regulatory submission, with more detailed findings from ACTION-1 expected to be presented at an upcoming medical meeting, potentially offering a novel alpha-isotope based option for patients.
The Unmet Need in Advanced GEP-NETs Post-Lutathera Progression
Despite meaningful advances in systemic therapy for advanced GEP-NETs, the treatment landscape remains constrained by limited durability of response, resistance mechanisms, and a lack of validated sequencing strategies following first-line and subsequent therapies. The heterogeneity of somatostatin receptor (SSTR) expression across tumor sites and grades further complicates treatment selection and response prediction.
Resistance to somatostatin analogues (SSAs): SSTR2 expression profiles vary significantly by primary tumor site and proliferative activity — SSTR2 immunoreactivity is significantly negatively correlated with the Ki-67 labeling index in foregut NETs and positively correlated in hindgut NETs. Rectal neuroendocrine cells exhibit significantly lower SSTR2 positive rates than those in the stomach and duodenum, contributing to differential SSA efficacy across GI-NET subtypes. Mechanisms of both up-front and acquired resistance to SSAs remain an active area of investigation.
Limited and non-durable benefit from PRRT: While Lu-177-DOTATATE demonstrated a median PFS of 28.4 months versus 8.5 months for octreotide LAR 60 mg monthly in the NETTER-1 trial, a beneficial effect on overall survival awaits confirmation. After progression on PRRT, available salvage options are limited; re-treatment with Lu-DOTATATE has shown median PFS ranging from 6 to 22 months in the salvage setting, with toxicity predominantly hematologic (anemia and neutropenia, grade 3/4 in 4–7% of cases), but no randomized phase III data or consensus on optimal re-treatment cycles or dosing exist.
Toxicity and feasibility challenges with combination strategies: The combination of everolimus at 10 mg daily with Lu-DOTATATE was found not to be feasible, with grade 3 toxicities occurring in 36% of patients (including fatigue, infection, pneumonitis, neutropenia, and stroke), and all patients at the 10 mg everolimus level requiring dose reduction or complete cessation. In the NETTLE phase I study, the maximum tolerated dose of everolimus in combination with Lu-177-octreotate was established at 7.5 mg daily. In a real-world cohort, patients previously treated with both PRRT and chemotherapy prior to everolimus experienced a 12-fold increased risk for severe toxicity, with grade 3–4 adverse events in 86.8% of cases.
Absence of a validated post-first-line treatment sequence: Following first-line SSA therapy, there is no clear information indicating a preferred treatment sequence, and the treatment approach must be individualized based on each patient's characteristics. Landmark randomized trials using systemic therapies — including PROMID, CLARINET, RADIANT-3, RADIANT-4, sunitinib, and NETTER-1 — have not shown efficacy in reducing liver tumor burden in patients with stage IV GEP-NETs with liver metastases.
Biomarker gaps limiting patient selection: Circulating hsa-miR-5096 has been identified as an independent predictor of 6-month PFS and 12-month overall survival upon PRRT, and inversely correlates with SSTR2 expression in pancreatic NET tissue and Gallium-DOTATOC uptake values. Exosome-mediated delivery of hsa-miR-5096 may promote SSTR2 heterogeneity and thus resistance to PRRT. Despite these findings, validated, clinically actionable biomarkers for prospective patient selection across treatment modalities remain lacking.
Interference between SSAs and PRRT radioligand binding: Conventional SSAs such as octreotide reduce radioligand uptake at low, clinically relevant concentrations (7.3–25.4 nM) and lead to further significant reduction at higher concentrations (73–508 nM), necessitating SSA discontinuation prior to PRRT and creating a symptom control gap in patients with carcinoid syndrome during the treatment window.
ACTION-1: RYZ101's Pivotal Phase 3 Design and Primary Endpoint
Several pivotal randomized controlled trials have established the evidence base for somatostatin receptor–targeting therapies in advanced GEP-NETs, spanning somatostatin analogs (SSAs) and peptide receptor radionuclide therapy (PRRT). These trials vary in patient population, comparator arms, and primary endpoints, collectively informing current treatment sequencing across tumor grades.
| Trial | Design | Population | Treatment Arms | Primary Endpoint | Key Primary Endpoint Result |
|---|---|---|---|---|---|
| PROMID | Placebo-controlled, double-blind, prospective, randomized, Phase IIIB | Treatment-naïve, well-differentiated metastatic midgut NETs | Octreotide LAR 30 mg IM monthly vs. placebo | Time to tumor progression | Median time to tumor progression: 14.3 months (octreotide LAR) vs. 6 months (placebo); HR = 0.34 (95% CI: 0.20–0.59; P = .000072) |
| CLARINET | Randomized, double-blind, placebo-controlled | Metastatic grade 1/2 (Ki-67 ≤10%) non-functioning pancreatic/intestinal NETs | Lanreotide Autogel 120 mg every 4 weeks for 96 weeks vs. placebo | Progression-free survival (PFS) | Median lanreotide PFS (core + OLE): 32.8 months (95% CI: 30.9–68.0); placebo median PFS: 18 months |
| CLARINET OLE | Open-label extension of CLARINET | Patients with stable disease (either arm) or progressive disease (placebo only) at core study end | All patients received lanreotide 120 mg every 28 days | Long-term safety and efficacy (PFS) | Median PFS in LAN-LAN group: 38.5 months (95% CI: 30.9–59.4); time to further PD after placebo-to-lanreotide switch (n=32): 14.0 months (95% CI: 10.1–not reached) |
| NETTER-1 | Phase 3, randomized | Somatostatin receptor-positive GEP-NETs (foregut, midgut, hindgut) | 177Lu-DOTATATE vs. high-dose octreotide LAR 60 mg monthly | Progression-free survival (PFS) | Median PFS: 28.4 months (177Lu-DOTATATE) vs. 8.5 months (octreotide LAR 60 mg) |
| NETTER-2 | Open-label, parallel-group, randomized, Phase 3 | Newly diagnosed, advanced, well-differentiated higher grade 2–3 (Ki-67 ≥10% and ≤55%), SSTR-positive GEP-NETs | 177Lu-DOTATATE (4 cycles) + octreotide LAR 30 mg every 8 weeks then every 4 weeks vs. high-dose octreotide LAR 60 mg every 4 weeks (2:1 randomization; 226 patients from 9 countries) | Progression-free survival (PFS) | Median PFS: 22.8 months (95% CI: 19.4–NE) with 177Lu-DOTATATE vs. 8.5 months (95% CI: 7.7–13.8) in control arm |
| PReCedeNT | Single-center, randomized, open-label, Phase 3 | FDG-avid, well-differentiated GEP-NETs | PRRT (177Lu-DOTATATE) alone vs. PRRT + capecitabine and temozolomide (CAPE-TEM); 1:1 randomization; planned n=162 | Progression-free survival (PFS) | Ongoing; sample size based on assumption that chemotherapy addition would improve PFS by an absolute value of 15% vs. NETTER-1 PRRT arm |
| LuCAP | Investigator-initiated, parallel-group, open-label, Phase 2 | Grade 1/2 GEP-NETs, progressive, somatostatin receptor-positive on Ga-DOTANOC PET/CT; n=72 | 177Lu-DOTATATE (~7.4 GBq/cycle, up to 4 cycles, every 8 weeks) + capecitabine (1,250 mg/m²/day, days 0–14 per cycle) vs. 177Lu-DOTATATE alone; 1:1 randomization | Objective response rate (ORR) | ORR: 33.3% (experimental) vs. 30.6% (control); P = 0.800 (not significant) |
| LUMEN | Prospective, Phase II | Progressive GEP-NETs; n=37 | 4 cycles of 7.4 GBq 177Lu-DOTATATE | Prediction of PRRT outcome using multimodality imaging and tumor dosimetry; PFS and best objective response (RECIST 1.1) as correlative endpoints | Median PFS: 28 months; patients receiving minimal C1 dose ≥35 Gy in all target lesions had significantly longer PFS (48.1 vs. 26.2 months; HR 0.37; 95% CI 0.17–0.82; P = 0.02) |
RYZ101's Potential to Reshape the GEP-NET Treatment Landscape
The treatment landscape for advanced somatostatin receptor–expressing GEP-NETs has evolved considerably, with established standards including somatostatin analogues, peptide receptor radionuclide therapy (PRRT) with 177Lu-DOTATATE, everolimus, and sunitinib providing meaningful but finite disease control. In the phase 3 NETTER-2 trial, first-line 177Lu-DOTATATE plus octreotide LAR 30 mg demonstrated a median progression-free survival (PFS) of 22.8 months (95% CI 19.4–not estimable) versus 8.5 months (95% CI 7.7–13.8) with high-dose octreotide LAR 60 mg, with benefit observed regardless of NET grade (G2 or G3) or site of origin (pancreatic or gastrointestinal). In the phase 3 CABINET trial, cabozantinib at 60 mg daily significantly improved PFS versus placebo in previously treated patients: median PFS of 8.4 months versus 3.9 months in extrapancreatic NETs (stratified hazard ratio 0.38; 95% CI 0.25–0.59; P<0.001) and 13.8 months versus 4.4 months in pancreatic NETs (stratified hazard ratio 0.23; 95% CI 0.12–0.42; P<0.001), with confirmed objective response rates of 5% and 19%, respectively, compared with 0% for placebo. Grade 3 or higher adverse events occurred in 62–65% of cabozantinib-treated patients versus 23–27% with placebo, with common high-grade events including hypertension, fatigue, diarrhea, and thromboembolic events.
Among other investigational approaches, the phase IIa trial of foslinanib (CVM-1118), a novel oral anti-vasculogenic mimicry agent, reported a median PFS of 10.5 months (95% CI 5.6–22.3) in 35 efficacy-evaluable patients with grade 1–2 pancreatic or gastrointestinal NETs refractory to one or more prior therapies, with a disease control rate of 77%, an objective response rate of 3%, and a median overall survival not reached (95% CI 23.8–not reached); treatment-related adverse events occurred in 44% of patients, mostly grades 1–2, with no serious events. The phase 2 study of cabozantinib combined with metronomic temozolomide in 37 patients with advanced progressive well-differentiated NETs reported a clinical benefit rate of 100% (95% CI 89.5–100%) and a median PFS of 28.5 months (95% CI 16.8–28.5 months) after a median follow-up of 19.2 months, though the primary endpoint of overall response rate (15%; 95% CI 5–31%) was not met; the 3-year overall survival rate was 68.5% (±9.1%), and MGMT deficiency and c-MET expression were associated with response. In a real-world propensity score–matched analysis, apatinib combined with CAPTEM demonstrated a median PFS not reached (95% CI 36.6–not reached) versus 17.9 months (95% CI 8.0–18.0) with sunitinib (hazard ratio 0.17; 95% CI 0.08–0.36; P<0.001), and a median overall survival of 52.0 months (95% CI 48.1–58.0) versus 16.4 months (95% CI 12.7–22.1) with sunitinib (hazard ratio 0.10; 95% CI 0.05–0.22; P<0.001), though the retrospective design limits interpretability.
Combination and retreatment strategies with established agents have also been evaluated. The randomized phase 2 LuCAP trial found that adding low-dose capecitabine to 177Lu-DOTATATE did not improve outcomes over 177Lu-DOTATATE alone in grade 1/2 GEP-NETs: objective response rates were 33.3% versus 30.6% (P=0.800), disease control rates were 88.9% versus 91.7% (P=1.000), and estimated median PFS was 29 months versus 31 months (P=0.401), with median overall survival not reached in either arm. A retrospective U.S. study of 177Lu-DOTATATE retreatment in 31 patients with progressive NETs reported a median PFS of 9.6 months and median overall survival of 12.6 months after retreatment, compared with 20.2 months and 42.6 months, respectively, after initial treatment, with clinically significant hematotoxicity in 3 patients on retreatment and no grade 3 or 4 nephrotoxicity observed. Biomarker-driven analyses further suggest that PI3K/AKT/mTOR pathway alterations are associated with a significantly higher disease control rate with everolimus (85.7% vs. 28.6%; OR 13.0; 95% CI 1.40–199.5; P=0.009), while DDR and cell-cycle pathway alterations indicated reduced benefit, underscoring the potential for pathway-based patient selection to refine treatment decisions across both investigational and standard-of-care regimens.
RYZ101's Breakthrough: A New Horizon for Advanced GEP-NETs
The positive Phase 3 results for Bristol Myers Squibb's RYZ101 represent a pivotal moment for patients battling advanced gastroenteropancreatic neuroendocrine tumors (GEP-NETs) who have exhausted current treatment options. For years, lutetium-177 (177Lu)-DOTATATE, marketed as Lutathera, has been a cornerstone of peptide receptor radionuclide therapy (PRRT) for somatostatin receptor-positive GEP-NETs, demonstrating significant improvements in progression-free and overall survival. However, a substantial portion of patients eventually experience disease progression, leaving a critical unmet need for subsequent effective therapies.
RYZ101, an actinium-225 (225Ac)-based radiopharmaceutical, heralds the arrival of a new generation of alpha-emitting PRRT. Unlike beta-emitters, alpha particles deliver higher energy over a shorter range, leading to more potent and targeted cell death through double-stranded DNA breaks, theoretically minimizing damage to surrounding healthy tissues. This mechanism offers a compelling advantage, particularly in a patient population that has already undergone beta-PRRT.
This breakthrough positions BMS to potentially redefine the treatment paradigm for advanced GEP-NETs, establishing RYZ101 as a crucial second-line option. The strategic acquisition of RayzeBio underscores the company's commitment to leading in the burgeoning alpha-radiopharmaceutical space. However, the journey ahead involves careful consideration of several factors:
Long-term Safety: While initial safety data are promising, the distinct toxicity profile of alpha-emitters, including potential for subclinical hypothyroidism and the known risk of persistent hematologic dysfunction seen with 177Lu-DOTATATE, necessitates vigilant long-term monitoring.
Competitive Dynamics: The success of RYZ101 will undoubtedly spur further innovation in alpha-PRRT, potentially leading to a more crowded market with other novel agents.
Treatment Integration: Defining the optimal sequencing and potential combination strategies with other therapies, such as targeted agents or chemotherapy, will be crucial for maximizing patient benefit and ensuring broad clinical adoption.
Ultimately, RYZ101's success offers renewed hope for patients with advanced GEP-NETs, signaling a significant step forward in personalized oncology and the continued evolution of radioligand therapy.
Frequently Asked Questions
References
- [1] Gaiani F, de'Angelis N et al.. Pediatric gastroenteropancreatic neuroendocrine tumor: A case report and review of the literature. Medicine. 2019 Sep. 31517859
- [2] Lv Y, Han X et al.. Risk factors affecting prognosis in metachronous liver metastases from WHO classification G1 and G2 gastroenteropancreatic neuroendocrine tumors after initial R0 surgical resection. BMC cancer. 2019 Apr 8. 30961559
- [3] Caplin ME, Pavel M et al.. Lanreotide autogel/depot in advanced enteropancreatic neuroendocrine tumours: final results of the CLARINET open-label extension study. Endocrine. 2021 Feb. 33052555
- [4] Sheikh-Ahmad M, Agbarya A et al.. Comparison of Mitotic Count and Ki-67 Index in Grading Gastroenteropancreatic Neuroendocrine Tumors and Their Association with Metastases. Biomedicines. 2025 Oct 8. 41153728
- [5] Dromain C, Loaiza-Bonilla A et al.. Novel Tumor Growth Rate Analysis in the Randomized CLARINET Study Establishes the Efficacy of Lanreotide Depot/Autogel 120 mg with Prolonged Administration in Indolent Neuroendocrine Tumors. The oncologist. 2021 Apr. 33393112
- [6] Saglam S, Hacisahinogullari H et al.. Outcomes of first-line long-acting octreotide treatment in non-functional, advanced gastroenteropancreatic neuroendocrine tumors. Journal of B.U.ON. : official journal of the Balkan Union of Oncology. 2015 Sep-Oct. 26537065
- [7] Neychev V, Steinberg SM et al.. Mutation-targeted therapy with sunitinib or everolimus in patients with advanced low-grade or intermediate-grade neuroendocrine tumours of the gastrointestinal tract and pancreas with or without cytoreductive surgery: protocol for a phase II clinical trial. BMJ open. 2015 May 19. 25991462
- [8] Faivre S, Castellano D et al.. Pancreatic NETs: where do we stand now?. Cancer metastasis reviews. 2014 Mar. 24452757
- [9] Satapathy S, Mittal BR et al.. (177)Lu-DOTATATE Plus Radiosensitizing Capecitabine Versus Octreotide Long-Acting Release as First-Line Systemic Therapy in Advanced Grade 1 or 2 Gastroenteropancreatic Neuroendocrine Tumors: A Single-Institution Experience. JCO global oncology. 2021 Jul. 34288699
- [10] Kröcher A, Folprecht G et al.. Successful Combination of Olaparib and (225)Ac-Dotatate in a Patient with Neuroendocrine Tumor G3 and BRCA Mutation. Case reports in oncology. 2023 Jan-Dec. 37900794
- [11] Xue JS, Yang Y et al.. Management of liver metastases from non-functional gastroenteropancreatic neuroendocrine tumors: a systematic review. Frontiers in endocrinology. 2025. 40778271
- [12] Panzuto F, Rinzivillo M et al.. Real-world study of everolimus in advanced progressive neuroendocrine tumors. The oncologist. 2014 Sep. 25117065
- [13] Cives M, Kunz PL et al.. Phase II clinical trial of pasireotide long-acting repeatable in patients with metastatic neuroendocrine tumors. Endocrine-related cancer. 2015 Feb. 25376618
- [14] McClellan K, Chen EY et al.. Therapy Resistant Gastroenteropancreatic Neuroendocrine Tumors. Cancers. 2022 Sep 29. 36230691
- [15] Mirakhur B, Pavel ME et al.. BIOCHEMICAL RESPONSES IN SYMPTOMATIC AND ASYMPTOMATIC PATIENTS WITH NEUROENDOCRINE TUMORS: POOLED ANALYSIS OF 2 PHASE 3 TRIALS. Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists. 2018 Aug 7. 30084687
- [16] Diamantopoulos LN, Laskaratos FM et al.. Antiproliferative Effect of Above-Label Doses of Somatostatin Analogs for the Management of Gastroenteropancreatic Neuroendocrine Tumors. Neuroendocrinology. 2021. 32541155
- [17] Mileva M, Marin G et al.. Prediction of (177)Lu-DOTATATE PRRT Outcome Using Multimodality Imaging in Patients with Gastroenteropancreatic Neuroendocrine Tumors: Results from a Prospective Phase II LUMEN Study. Journal of nuclear medicine : official publication, Society of Nuclear Medicine. 2024 Feb 1. 38164576
- [18] Ligero M, Hernando J et al.. Radiomics and outcome prediction to antiangiogenic treatment in advanced gastroenteropancreatic neuroendocrine tumours: findings from the phase II TALENT trial. BJC reports. 2023 Aug 2. 39516643
- [19] Bodei L, Raj N et al.. Interim Analysis of a Prospective Validation of 2 Blood-Based Genomic Assessments (PPQ and NETest) to Determine the Clinical Efficacy of (177)Lu-DOTATATE in Neuroendocrine Tumors. Journal of nuclear medicine : official publication, Society of Nuclear Medicine. 2023 Apr. 36396457
- [20] Patel D, Chan D et al.. Systemic therapies for advanced gastroenteropancreatic neuroendocrine tumors. Expert review of endocrinology & metabolism. 2016 Jul. 30058926
Contact Us
Address
350 Springfield Avenue,
Suite #200 Summit, NJ 07901
For General Inquiry
info@pienomial.com
